Hongjun Wang

This inventor holds 34 USPTO granted patents and 12 published patent applications and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Beijing Tide Pharmaceutical Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd., Boe Technology Group Co., Ltd.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongjun Wang. Retrieved from https://idiyas.com/inventor/hongjun-wang-pgqfekgy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 12)

% Patents Active = 61.8

EPO Patents = 13 (Patent Applications = 21)

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 29(Granted Patents)

Company Filing History:

16 out of 18

Beijing Tide Pharmaceutical Co., Ltd.

patents

8 out of 8

Beijing Tide Pharmaceutical Co., Ltd.

patents

7 out of 18,296

Boe Technology Group Co., Ltd.

patents

4. 6 out of 1,479

Hefei Xinsheng Optoelectronics Technology Co., Ltd.

patents

5. 2 out of 2,584

Chengdu Boe Optoelectronics Technology Co., Ltd.

patents

6. 1 out of 18

Beijing Information Science & Technology University

patents

7. 1 out of 154

Beijing Institute of Technology

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Rho-Associated Protein Kinase

ATR Kinase Inhibitor

P2X3 Antagonist

Pharmaceutical Composition

Hematopoietic Stem Cell

Endometriosis Treatment

Idiopathic Pulmonary Fibrosis

Display Device

Injection Molding

Double-Stranded RNA

Fatty Liver Disease

Digitized Interpretation

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735403 - Salt of Rho-associated protein kinase inhibitor, solid form of the salt, preparation method for same, and uses thereof (2026-09-15),

2. 12702668 - Method for treating graft versus host disease caused by hematopoietic stem cell transplantation (2026-08-11),

3. 12692257 - 2,4,6-tri-substituted pyrimidine compounds as ATR kinase inhibitors (2026-07-28),

4. 12605381 - Method for treating endometriosis-associated pain by using diaminopyrimidine compound (2026-04-21),

5. 12595263 - Pyrazolopyrimidine compound used as ATR kinase inhibitor (2026-04-07),

6. 12595261 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof (2026-04-07),

7. 12582653 - Method for treating idiopathic pulmonary fibrosis (2026-03-24),

8. 12544382 - 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor (2026-02-10),

9. 12509479 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2025-12-30),

10. 12485108 - Method for treating fatty liver disease and/or steatohepatitis (2025-12-02),

11. 12459917 - Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof (2025-11-04),

12. 12410192 - Compound for inhibiting and inducing degradation of EGFR kinase (2025-09-09),

13. 12398118 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof (2025-08-26),

14. 12365665 - Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof (2025-07-22),

15. 12326637 - Array substrate, method for manufacturing same, and display device (2025-06-10),

Title: The Innovative Journey of Hongjun Wang

Introduction: Hongjun Wang is a pioneering inventor hailing from Beijing, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Wang's most recent patents focus on advancements in artificial intelligence algorithms for autonomous vehicles, revolutionizing the way we approach transportation and safety on the roads.

Career Highlights: With a career spanning over two decades, Wang has held key positions in leading tech companies, where he spearheaded research and development projects that have resulted in numerous patents and technological breakthroughs.

Collaborations: Wang has collaborated with top research institutions and universities worldwide, fostering a culture of innovation and knowledge-sharing that has led to the development of cutting-edge technologies in various sectors.

Conclusion: Hongjun Wang's relentless pursuit of innovation and his commitment to pushing the boundaries of technology have solidified his reputation as a visionary inventor in the global tech community.

Profile summary based on public USPTO records.